A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

​ Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: BMS-986504; Drug: Gemcitabine; Drug: Nab-paclitaxel; Drug: Placebo

Sponsors: Bristol-Myers Squibb

Not yet recruiting Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Drug: BMS-986504; Drug: Gemcitabine; Drug: Nab-paclitaxel; Drug: Placebo
Sponsors: Bristol-Myers Squibb
Not yet recruiting